Zaki Mohamed 4

What Happened
Zaki Mohamed, Chief Medical Officer of ADC Therapeutics (ADCT), was granted 213,900 restricted stock units (RSUs) on June 30, 2026. The award was reported as an acquisition at $0.00 (no cash exchanged). Each RSU represents a contingent right to one share of ADC Therapeutics common stock upon vesting.

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (within the two-business-day reporting window).
• Amount: 213,900 RSUs; reported acquisition price: $0.00; aggregate dollar value at grant not stated (value will depend on future stock price).
• Shares owned after transaction: not specified in the filing.
• Footnote: RSUs vest on the earlier of (i) June 30, 2027 or (ii) termination of employment by the issuer without cause or by the reporting person for good reason, subject to continued employment on the vesting date. Each RSU converts to one share upon vesting.
• Transaction code: A = Award/Grant.

Context
This is a compensation award, not an open-market purchase or sale. RSU grants are common executive compensation and only become actual shares if/when vesting conditions are met; they do not necessarily signal immediate insider sentiment about the stock.